Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 4/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27203455 | 0.84 | ADORA2A (0.43) | SMN1; SMN2ALDH1A1MAPK1MAPTADORA2A | |
| SCHEMBL29112547 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1MAPK1ADCY10MAPT | |
| SCHEMBL22342896 | 0.73 | KDM4E (0.50) | TYK2 | |
| SCHEMBL29112569 | 0.70 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1ADCY10MAPTNPC1 | |
| SCHEMBL15307047 | 0.70 | KDM4E (0.53) | SMN1; SMN2ALDH1A1MAPK1HTR6MAPT | |
| SCHEMBL21947188 | 0.69 | TYK2 (0.61) | TYK2 | |
| SCHEMBL27203449 | 0.68 | ADORA2A (0.47) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL29112572 | 0.68 | MAPT (0.32) | MAPT | |
| SCHEMBL21313032 | 0.67 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1MAPK1MAPTNPC1 | |
| SCHEMBL29112561 | 0.66 | TDP1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132517-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | GOHARMONY THERAPEUTICS (SHENZHEN) CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132517-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SRC, FLT3, BRAF | SMN1; SMN2 2368/4885ALDH1A1 4014/4885MAPK1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.